The DOI matches its Crossref record; 169 of the 169 references it cites were found in a registry or an index.
Li-Fraumeni Syndrome
Open accessAbstract
Li-Fraumeni syndrome (LFS) is a classic cancer predisposition disorder that is commonly associated with germline mutations of the p53 tumor suppressor gene. Examination of the wide spectrum of adult-onset and childhood cancers and the distribution of p53 mutations has led to a greater understanding of cancer genotype-phenotype correlations. However, the complex LFS phenotype is not readily explained by the simple identification of germline p53 mutations in affected individuals. Recent work has identified genetic events that modify the LFS phenotype. These include intragenic polymorphisms, mutations/polymorphisms of genes in the p53 regulatory pathway, as well as more global events such as aberrant copy number variation and telomere attrition. These genetic events may, in part, explain the breadth of tumor histiotypes within and across LFS families, the apparent accelerated age of onset within families, and the range of clinical outcomes among affected family members. This review will examine the clinical and genetic definitions of LFS and offer insight into how lessons learned from the study of this rare disorder may inform similar questions in other familial cancer syndromes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“LFS was first discovered in 1969 and is characterized by the early onset of breast cancer as well as various sarcomas, adrenocortical carcinomas, gliomas, leukemias, and other cancers, especially in children and early adulthood.171”
From p53: from understanding its structure to advances in therapeutic targeting (2026) · cites this paper as [171]
In the citing paper
“Germline mutation of TP53 in the heterozygous LOF form usually presents with a rare autosomally dominant genetic disease with a significantly increased risk of cancer development known as Li-Fraumeni syndrome (LFS).”
From p53: from understanding its structure to advances in therapeutic targeting (2026) · cites this paper as [171]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Transactivation of the EGR1 Gene Contributes to Mutant p53 Gain of Function
Weisz, L., Zalcenstein, A., Stambolsky, P., Cohen, Y., Goldfinger, N., Oren, M., & Rotter, V. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-1145 · Cited by 129
RetractedMutation and cancer: statistical study of retinoblastoma
Knudson, A. G. (1971) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.68.4.820 · Cited by 7,612
Lane, D. P. (1992) · Nature · doi:10.1038/358015a0 · Cited by 5,138
Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours
Donehower, L. A., Harvey, M., Slagle, B. L., McArthur, M. J., Montgomery, C. A., Butel, J. S., & Bradley, A. (1992) · Nature · doi:10.1038/356215a0 · Cited by 4,649
Germ Line p53 Mutations in a Familial Syndrome of Breast Cancer, Sarcomas, and Other Neoplasms
Malkin, D., Li, F. P., Strong, L. C., Fraumeni, J. F., Nelson, C. E., Kim, D. H., Kassel, J., Gryka, M. A., Bischoff, F. Z., Tainsky, M. A., et al. (1990) · Science · doi:10.1126/science.1978757 · Cited by 3,765
Self-citationRegulation of p53 stability by Mdm2
Kubbutat, M. H. G., Jones, S. N., & Vousden, K. H. (1997) · Nature · doi:10.1038/387299a0 · Cited by 3,312
T antigen is bound to a host protein in SY40-transformed cells
LANE, D. P., & CRAWFORD, L. V. (1979) · Nature · doi:10.1038/278261a0 · Cited by 2,394
Chromosome 17 Deletions and p53 Gene Mutations in Colorectal Carcinomas
Baker, S. J., Fearon, E. R., Nigro, J. M., Hamilton, S. R., Preisinger, A. C., Jessup, J. M., vanTuinen, P., Ledbetter, D. H., Barker, D. F., Nakamura, Y., et al. (1989) · Science · doi:10.1126/science.2649981 · Cited by 2,066
Tumor spectrum analysis in p53-mutant mice
Jacks, T., Remington, L., Williams, B. O., Schmitt, E. M., Halachmi, S., Bronson, R. T., & Weinberg, R. A. (1994) · Current Biology · doi:10.1016/s0960-9822(00)00002-6 · Cited by 2,051
Amplification of a gene encoding a p53-associated protein in human sarcomas
Oliner, J. D., Kinzler, K. W., Meltzer, P. S., George, D. L., & Vogelstein, B. (1992) · Nature · doi:10.1038/358080a0 · Cited by 1,949
Linzer, D. I. H., & Levine, A. J. (1979) · Cell · doi:10.1016/0092-8674(79)90293-9 · Cited by 1,813
Petitjean, A., Mathe, E., Kato, S., Ishioka, C., Tavtigian, S. V., Hainaut, P., & Olivier, M. (2007) · Human Mutation · doi:10.1002/humu.20495 · Cited by 1,598
Soft-Tissue Sarcomas, Breast Cancer, and Other Neoplasms: A Familial Syndrome?
LI, F. P., & FRAUMENI, J. F. (1969) · Annals of Internal Medicine · doi:10.7326/0003-4819-71-4-747 · Cited by 1,509
Pochon, S. (2005) · American Journal of Cancer · doi:10.2165/00024669-200504040-00008 · Cited by 1,424
Mutant p53 gain of function in two mouse models of Li-Fraumeni syndrome
Olive, K. P., Tuveson, D. A., Ruhe, Z. C., Yin, B., Willis, N. A., Bronson, R. T., Crowley, D., & Jacks, T. (2004) · Cell · doi:10.1016/j.cell.2004.11.004 · Cited by 1,308
A cancer family syndrome in twenty-four kindreds.
Li, F. P., Fraumeni, J. F., Mulvihill, J. J., Blattner, W. A., Dreyfus, M., Tucker, M., & Miller, R. (1988) · PubMed · Cited by 1,293
Bond, G. L., Hu, W., Bond, E. E., Robins, H., Lutzker, S. G., Arva, N. C., Bargonetti, J., Bartel, F., Taubert, H., Wuerl, P., et al. (2004) · Cell · doi:10.1016/j.cell.2004.11.022 · Cited by 1,265
Is a p53-Regulated Inhibitor of G2/M Progression
Hermeking, H., Lengauer, C., Polyak, K., He, T.-C., Zhang, L., Thiagalingam, S., Kinzler, K. W., & Vogelstein, B. (1997) · Molecular Cell · doi:10.1016/s1097-2765(00)80002-7 · Cited by 1,251
The CHEK2-Breast Cancer Consortium (2002) · Nature Genetics · doi:10.1038/ng879 · Cited by 1,104
Identification of p53 as a Sequence-Specific DNA-Binding Protein
Kern, S. E., Kinzler, K. W., Bruskin, A., Jarosz, D., Friedman, P., Prives, C., & Vogelstein, B. (1991) · Science · doi:10.1126/science.2047879 · Cited by 1,085
KILLER/DR5 is a DNA damage–inducible p53–regulated death receptor gene
Wu, G. S., Burns, T. F., McDonald, E. R., Jiang, W., Meng, R., Krantz, I. D., Kao, G., Gan, D.-D., Zhou, J.-Y., Muschel, R., et al. (1997) · Nature Genetics · doi:10.1038/ng1097-141 · Cited by 1,083
Gain of function of a p53 hot spot mutation in a mouse model of Li-Fraumeni syndrome
Lang, G. A., Iwakuma, T., Suh, Y.-A., Liu, G., Rao, V. A., Parant, J. M., Valentin-Vega, Y. A., Terzian, T., Caldwell, L. C., Strong, L. C., et al. (2004) · Cell · doi:10.1016/j.cell.2004.11.006 · Cited by 1,069
Oncogenic forms of p53 inhibit p53-regulated gene expression
Kern, S., Pietenpol, J., Thiagalingam, S., Seymour, A., Kinzler, K., & Vogelstein, B. (1992) · Science · doi:10.1126/science.1589764 · Cited by 940
Robson, M. E., Bradbury, A. R., Arun, B., Domchek, S. M., Ford, J. M., Hampel, H. L., Lipkin, S. M., Syngal, S., Wollins, D. S., & Lindor, N. M. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.63.0996 · Cited by 934
Heterozygous Germ Line hCHK2 Mutations in Li-Fraumeni Syndrome
Bell, D. W., Varley, J. M., Szydlo, T. E., Kang, D. H., Wahrer, D. C. R., Shannon, K. E., Lubratovich, M., Verselis, S. J., Isselbacher, K. J., Fraumeni, J. F., et al. (1999) · Science · doi:10.1126/science.286.5449.2528 · Cited by 904
p53 Activates the CD95 (APO-1/Fas) Gene in Response to DNA Damage by Anticancer Drugs
Müller, M., Wilder, S., Bannasch, D., Israeli, D., Lehlbach, K., Li-Weber, M., Friedman, S. L., Galle, P. R., Stremmel, W., Oren, M., et al. (1998) · The Journal of Experimental Medicine · doi:10.1084/jem.188.11.2033 · Cited by 878
Kato, S., Han, S.-Y., Liu, W., Otsuka, K., Shibata, H., Kanamaru, R., & Ishioka, C. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1431692100 · Cited by 874
Bcl-2 prolongs cell survival after Bax-induced release of cytochrome c
Rossé, T., Olivier, R., Monney, L., Rager, M., Conus, S., Fellay, I., Jansen, B., & Borner, C. (1998) · Nature · doi:10.1038/35160 · Cited by 870
Rausch, T., Jones, D. T. W., Zapatka, M., Stütz, A. M., Zichner, T., Weischenfeldt, J., Jäger, N., Remke, M., Shih, D., Northcott, P. A., et al. (2012) · Cell · doi:10.1016/j.cell.2011.12.013 · Cited by 865
Self-citationCurrent Medical Diagnosis and Treatment.
(1978) · Annals of Internal Medicine · doi:10.7326/0003-4819-88-5-725_6 · Cited by 830
(2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.03.189 · Cited by 751
DeLeo, A. B., Jay, G., Appella, E., Dubois, G. C., Law, L. W., & Old, L. J. (1979) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.76.5.2420 · Cited by 721
Gannon, J. V., Greaves, R., Iggo, R., & Lane, D. P. (1990) · The EMBO Journal · doi:10.1002/j.1460-2075.1990.tb08279.x · Cited by 688
Milner, J., & Medcalf, E. A. (1991) · Cell · doi:10.1016/0092-8674(91)90384-b · Cited by 612
Beyond Li Fraumeni Syndrome: Clinical Characteristics of Families With p53 Germline Mutations
Gonzalez, K. D., Noltner, K. A., Buzin, C. H., Gu, D., Wen-Fong, C. Y., Nguyen, V. Q., Han, J. H., Lowstuter, K., Longmate, J., Sommer, S. S., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.16.6959 · Cited by 609
Human Cancer Syndromes: Clues to the Origin and Nature of Cancer
Fearon, E. R. (1997) · Science · doi:10.1126/science.278.5340.1043 · Cited by 605
Structural aspects of the p53 protein in relation to gene evolution.
Soussi, T., de Fromentel, C. C., & May, P. (1990) · PubMed · Cited by 603
Wild-type p53 activates transcription in vitro
Farmer, G., Bargonetti, J., Zhu, H., Friedman, P., Prywes, R., & Prives, C. (1992) · Nature · doi:10.1038/358083a0 · Cited by 579
Comparative biology of mouse versus human cells: modelling human cancer in mice
Rangarajan, A., & Weinberg, R. A. (2003) · Nature Reviews Cancer · doi:10.1038/nrc1235 · Cited by 567
Multiple Primary Cancers in Families With Li-Fraumeni Syndrome
Hisada, M., Garber, J. E., Li, F. P., Fung, C. Y., & Fraumeni, J. F. (1998) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/90.8.606 · Cited by 557
Spontaneous and carcinogen-induced tumorigenesis in p53-deficient mice.
Harvey, M., McArthur, M. J., Montgomery, C. A., Butel, J. S., Bradley, A., & Donehower, L. A. (1993) · Nature Genetics · doi:10.1038/ng1193-225 · Cited by 542
Ribeiro, R. C., Sandrini, F., Figueiredo, B., Zambetti, G. P., Michalkiewicz, E., Lafferty, A. R., DeLacerda, L., Rabin, M., Cadwell, C., Sampaio, G., et al. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.161479898 · Cited by 541
(1996) · Journal of Clinical Oncology · doi:10.1200/jco.1996.14.5.1730 · Cited by 484
Olivier, M., Goldgar, D. E., Sodha, N., Ohgaki, H., Kleihues, P., Hainaut, P. L., & Eeles, R. A. (2003) · PubMed · Cited by 477
Prevalence and diversity of constitutional mutations in the p53 gene among 21 Li-Fraumeni families
Birch, Hartley, Tricker, Prosser, P., Condie, Kelsey, Harris, Jones, Binchy, Crowther, et al. (1994) · Cancer Research · Cited by 475
Zhan, Q., Antinore, M. J., Wang, X. W., Carrier, F., Smith, M. L., Harris, C. C., & Fornace, A. J. (1999) · Oncogene · doi:10.1038/sj.onc.1202667 · Cited by 474
Relative frequency and morphology of cancers in carriers of germline TP53 mutations
Birch, J. M., Alston, R. D., McNally, R. J., Evans, D. G. R., Kelsey, A. M., Harris, M., Eden, O. B., & Varley, J. M. (2001) · Oncogene · doi:10.1038/sj.onc.1204621 · Cited by 467
A CHEK2 Genetic Variant Contributing to a Substantial Fraction of Familial Breast Cancer
Vahteristo, P., Bartkova, J., Eerola, H., Syrjäkoski, K., Ojala, S., Kilpivaara, O., Tamminen, A., Kononen, J., Aittomäki, K., Heikkilä, P., et al. (2002) · The American Journal of Human Genetics · doi:10.1086/341943 · Cited by 467
A simple p53 functional assay for screening cell lines, blood, and tumors.
Flaman, J. M., Frebourg, T., Moreau, V, Charbonnier, F., Martin, C., Chappuis, P., Sappino, A. P., Limacher, I. M., Bron, L., & Benhattar, J. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.9.3963 · Cited by 454
Venkatachalam, S. (1998) · The EMBO Journal · doi:10.1093/emboj/17.16.4657 · Cited by 449
GermlineTP53 mutations and Li-Fraumeni syndrome
Varley, J. M. (2003) · Human Mutation · doi:10.1002/humu.10185 · Cited by 430
Villani, A., Tabori, U., Schiffman, J., Shlien, A., Beyene, J., Druker, H., Novokmet, A., Finlay, J., & Malkin, D. (2011) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70119-x · Cited by 423
Self-citationPrevalence and diversity of constitutional mutations in the p53 gene among 21 Li-Fraumeni families.
Birch, J. M., Hartley, A. L., Tricker, K. J., Prosser, J., Condie, A., Kelsey, A. M., Harris, M., Jones, P. H. M., Binchy, A., & Crowther, D. (1994) · PubMed · Cited by 421
Tumors associated with p53 germline mutations: a synopsis of 91 families.
Kleihues, P., Schäuble, B., Hausen, A. Z., Estève, J., & Ohgaki, H. (1997) · Europe PMC (PubMed Central) · Cited by 411
Rhabdomyosarcoma in Children: Epidemiologic Study and Identification of a Familial Caneer Syndrome
(1969) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/43.6.1365 · Cited by 397
Lavigueur, A., Maltby, V, Mock, D., Rossant, J., Pawson, T., & Bernstein, A. (1989) · Molecular and Cellular Biology · doi:10.1128/mcb.9.9.3982 · Cited by 394
Copy number variations and cancer
Shlien, A., & Malkin, D. (2009) · Genome Medicine · doi:10.1186/gm62 · Cited by 386
Self-citationMalkin, D., Jolly, K. W., Barbier, N., Look, A. T., Friend, S. H., Gebhardt, M. C., Andersen, T. I., Børresen, A.-L., Li, F. P., Garber, J., et al. (1992) · New England Journal of Medicine · doi:10.1056/nejm199205143262002 · Cited by 379
Self-citation(2000) · British Journal of Cancer · doi:10.1054/bjoc.2000.1167 · Cited by 372
The gene for human p53 cellular tumor antigen is located on chromosome 17 short arm (17p13).
McBride, O. W., Merry, D., & Givol, D. (1986) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.83.1.130 · Cited by 365
Ethical Issues With Genetic Testing in Pediatrics
Committee on Bioethics (2001) · Pediatrics · doi:10.1542/peds.107.6.1451 · Cited by 364
Germ-line p53 mutations predispose to a wide spectrum of early-onset cancers.
Nichols, K. E., Malkin, D. M., Garber, J. E., Fraumeni, J. F., & Li, F. P. (2001) · PubMed · Cited by 354
Self-citation2009 Version of the Chompret Criteria for Li Fraumeni Syndrome
Tinat, J., Bougeard, G., Baert-Desurmont, S., Vasseur, S., Martin, C., Bouvignies, E., Caron, O., Bressac-de Paillerets, B., Berthet, P., Dugast, C., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.22.7967 · Cited by 348
Enhanced proliferative potential in culture of cells from p53-deficient mice.
Tsukada, T., Tomooka, Y., Takai, S., Ueda, Y., Nishikawa, S.-I., Yagi, T., Tokunaga, T., Takeda, N., Suda, Y., & Abe, S. (1993) · PubMed · Cited by 341
Sensitivity and predictive value of criteria for p53 germline mutation screening
CHOMPRET, A., ABEL, A., STOPPA-LYONNET, D., BRUGIÈRES, L., PAGÈS, S., FEUNTEUN, J., & BONAÏTI-PELLIÉ, C. (2001) · Journal of Medical Genetics · doi:10.1136/jmg.38.1.43 · Cited by 341
Willis, A., Jung, E. J., Wakefield, T., & Chen, X. (2004) · Oncogene · doi:10.1038/sj.onc.1207396 · Cited by 330
Liu, G., Parant, J. M., Lang, G., Chau, P., Chavez-Reyes, A., El-Naggar, A. K., Multani, A., Chang, S., & Lozano, G. (2004) · Nature Genetics · doi:10.1038/ng1282 · Cited by 325
M OLECULAR M ECHANISMS FOR G ENOMIC D ISORDERS
Inoue, K., & Lupski, J. R. (2002) · Annual Review of Genomics and Human Genetics · doi:10.1146/annurev.genom.3.032802.120023 · Cited by 318
Presymptomatic DNA testing and prophylactic surgery in families with a BRCA1 or BRCA2 mutation
Meijers-Heijboer, E., Verhoog, L., Brekelmans, C., Seynaeve, C., Tilanus-Linthorst, M., Wagner, A., Dukel, L., Devilee, P., van den Ouweland, A., van Geel, A., et al. (2000) · The Lancet · doi:10.1016/s0140-6736(00)02347-3 · Cited by 307
Proteolytic Cleavage of Human p53 by Calpain: a Potential Regulator of Protein Stability
Kubbutat, M. H. G., & Vousden, K. H. (1997) · Molecular and Cellular Biology · doi:10.1128/mcb.17.1.460 · Cited by 307
Weischer, M., Bojesen, S. E., Ellervik, C., Tybjærg-Hansen, A., & Nordestgaard, B. G. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.12.5922 · Cited by 306
Psychological impact of genetic testing for cancer susceptibility: an update of the literature
Meiser, B. (2005) · Psycho-Oncology · doi:10.1002/pon.933 · Cited by 303
A novel mechanism of tumorigenesis involving pH-dependent destabilization of a mutant p53 tetramer
DiGiammarino, E. L., Lee, A. S., Cadwell, C., Zhang, W., Bothner, B., Ribeiro, R. C., Zambetti, G., & Kriwacki, R. W. (2002) · Nature Structural Biology · doi:10.1038/nsb730 · Cited by 294
Tumour incidence, spectrum and ploidy in mice with a large deletion in the p53 gene.
Purdie, C. A., Harrison, D. J., Peter, A., Dobbie, L., White, S., Howie, S., Salter, D. M., Bird, C., Wyllie, A. H., & Hooper, M. L. (1994) · PubMed · Cited by 290
MDM2 SNP309 accelerates tumor formation in a gender-specific and hormone-dependent manner
Bond, G. L., Hirshfield, K. M., Kirchhoff, T., Alexe, G., Bond, E. E., Robins, H., Bartel, F., Taubert, H., Wuerl, P., Hait, W., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-0180 · Cited by 287
Follow-up study of twenty-four families with Li-Fraumeni syndrome.
Garber, J. E., Goldstein, A. M., Kantor, A. F., Dreyfus, M., Fraumeni, J. F., & Li, F. P. (1991) · PubMed · Cited by 275
The role of tetramerization in p53 function
Chène, P. (2001) · Oncogene · doi:10.1038/sj.onc.1204373 · Cited by 271
The p53-deficient mouse: a model for basic and applied cancer studies
Donehower, L. A. (1996) · Seminars in Cancer Biology · doi:10.1006/scbi.1996.0035 · Cited by 264
Germ-line mutations of TP53 in Li-Fraumeni families: an extended study of 39 families.
Varley, J. M., McGown, G., Thorncroft, M. R., Santibanez‐Koref, M., Kelsey, A. M., Tricker, K. J., Evans, D. G., & Birch, J. M. (1997) · PubMed · Cited by 263
Screening patients for heterozygous p53 mutations using a functional assay in yeast
Ishioka, C., Frebourg, T., Yan, Y.-X., Vidal, M., Friend, S. H., Schmidt, S., & Iggo, R. (1993) · Nature Genetics · doi:10.1038/ng1093-124 · Cited by 243
Molecular basis of the Li-Fraumeni syndrome: an update from the French LFS families
Bougeard, G., Sesboüé, R., Baert-Desurmont, S., Vasseur, S., Martin, C., Tinat, J., Brugières, L., Chompret, A., Paillerets, B. B.-D., Stoppa-Lyonnet, D., et al. (2008) · Journal of Medical Genetics · doi:10.1136/jmg.2008.057570 · Cited by 230
Germline p53 Mutations in a Cohort with Childhood Sarcoma: Sex Differences in Cancer Risk
Hwang, S.-J., Lozano, G., Amos, C. I., & Strong, L. C. (2003) · The American Journal of Human Genetics · doi:10.1086/374567 · Cited by 229
The CHEK2 gene and inherited breast cancer susceptibility
Nevanlinna, H., & Bartek, J. (2006) · Oncogene · doi:10.1038/sj.onc.1209877 · Cited by 219
Achatz, M. I. W., Olivier, M., Calvez, F. L., Martel-Planche, G., Lopes, A., Rossi, B. M., Ashton-Prolla, P., Giugliani, R., Palmero, E. I., Vargas, F. R., et al. (2007) · Cancer Letters · doi:10.1016/j.canlet.2005.12.039 · Cited by 217
Bougeard, G., Baert-Desurmont, S., Tournier, I., Vasseur, S., Martin, C., Brugieres, L., Chompret, A., Bressac-de Paillerets, B., Stoppa-Lyonnet, D., Bonaiti-Pellie, C., et al. (2006) · Journal of Medical Genetics · doi:10.1136/jmg.2005.037952 · Cited by 217
Vahteristo, P., Tamminen, A., Karvinen, P., Eerola, H., Eklund, C., Aaltonen, L. A., BLOMQVIST, C. P., Aittomäki, K., & Nevanlinna, H. A. (2001) · PubMed · Cited by 217
Heymann, S., Delaloge, S., Rahal, A., Caron, O., Frebourg, T., Barreau, L., Pachet, C., Mathieu, M.-C., Marsiglia, H., & Bourgier, C. (2010) · Radiation Oncology · doi:10.1186/1748-717x-5-104 · Cited by 213
Germline mutations in the TP53 gene.
Eeles, R. A. (1995) · PubMed · Cited by 211
Excessive genomic DNA copy number variation in the Li–Fraumeni cancer predisposition syndrome
Shlien, A., Tabori, U., Marshall, C. R., Pienkowska, M., Feuk, L., Novokmet, A., Nanda, S., Druker, H., Scherer, S. W., & Malkin, D. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0802970105 · Cited by 203
Self-citationPrediction of pathogenic mutations in patients with early-onset breast cancer by family history
Lalloo, F., Varley, J., Ellis, D., Moran, A., O'Dair, L., Pharoah, P., & Evans, D. G. R. (2003) · The Lancet · doi:10.1016/s0140-6736(03)12856-5 · Cited by 202
Birch, J. M., Blair, V., Kelsey, A. M., Evans, D. G., Harris, M., Tricker, K. J., & Varley, J. M. (1998) · Oncogene · doi:10.1038/sj.onc.1202033 · Cited by 200
High metastatic potential in mice inheriting a targeted p53 missense mutation
Liu, G., McDonnell, T. J., Montes de Oca Luna, R., Kapoor, M., Mims, B., El-Naggar, A. K., & Lozano, G. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.8.4174 · Cited by 199
Development of Spontaneous Mammary Tumors in BALB/c p53 Heterozygous Mice
Kuperwasser, C., Hurlbut, G. D., Kittrell, F. S., Dickinson, E. S., Laucirica, R., Medina, D., Naber, S. P., & Jerry, D. J. (2000) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)64853-5 · Cited by 190
Genetic testing in asymptomatic minors: Background considerations towards ESHG Recommendations
on behalf of the Public and Professional Policy Committee (PPPC) of the European Society of Human Genetics (ESHG), Borry, P., Evers-Kiebooms, G., Cornel, M. C., Clarke, A., & Dierickx, K. (2009) · European Journal of Human Genetics · doi:10.1038/ejhg.2009.25 · Cited by 183
Bond, G. L., Hu, W., & Levine, A. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-0825 · Cited by 176
BRCA1, BRCA2 and TP53 mutations in very early-onset breast cancer with associated risks to relatives
Lalloo, F., Varley, J., Moran, A., Ellis, D., O’Dair, L., Pharoah, P., Antoniou, A., Hartley, R., Shenton, A., Seal, S., et al. (2006) · European Journal of Cancer · doi:10.1016/j.ejca.2005.11.032 · Cited by 175
High frequency of de novo mutations in Li–Fraumeni syndrome
Gonzalez, K. D., Buzin, C. H., Noltner, K. A., Gu, D., Li, W., Malkin, D., & Sommer, S. S. (2009) · Journal of Medical Genetics · doi:10.1136/jmg.2008.058958 · Cited by 170
Self-citationGenetic testing in asymptomatic minors: recommendations of the European Society of Human Genetics
Recommendations of the European Society of Human Genetics (2009) · European Journal of Human Genetics · doi:10.1038/ejhg.2009.26 · Cited by 167
Penetrance of adrenocortical tumours associated with the germline TP53 R337H mutation
Figueiredo, B. C., Sandrini, R., Zambetti, G. P., Pereira, R. M., Cheng, C., Liu, W., Lacerda, L., Pianovski, M. A., Michalkiewicz, E., Jenkins, J., et al. (2006) · Journal of Medical Genetics · doi:10.1136/jmg.2004.030551 · Cited by 166
Garritano, S., Gemignani, F., Palmero, E. I., Olivier, M., Martel-Planche, G., Le Calvez-Kelm, F., Brugiéres, L., Vargas, F. R., Brentani, R. R., Ashton-Prolla, P., et al. (2010) · Human Mutation · doi:10.1002/humu.21151 · Cited by 153
Pinto, E. M., Billerbeck, A. E. C., Villares, M. C. B. F., Domenice, S., Mendonça, B. B., & Latronico, A. C. (2004) · Arquivos Brasileiros de Endocrinologia & Metabologia · doi:10.1590/s0004-27302004000500009 · Cited by 153
Two metachronous tumors in the radiotherapy fields of a patient with Li‐Fraumeni syndrome
Limacher, J., Frébourg, T., Natarajan‐Amé, S., & Bergerat, J. (2001) · International Journal of Cancer · doi:10.1002/ijc.1021 · Cited by 151
Younger Age of Cancer Initiation Is Associated with Shorter Telomere Length in Li-Fraumeni Syndrome
Tabori, U. Y., Nanda, S., Druker, H. A., Lees, J., & Malkin, D. M. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-3682 · Cited by 151
Self-citationRapamycin extends lifespan and delays tumorigenesis in heterozygous p53+/− mice
Komarova, E. A., Antoch, M. P., Novototskaya, L. R., Chernova, O. B., Paszkiewicz, G., Leontieva, O. V., Blagosklonny, M. V., & Gudkov, A. V. (2012) · Aging · doi:10.18632/aging.100498 · Cited by 146
Dorval, M., Patenaude, A. F., Schneider, K. A., Kieffer, S. A., DiGianni, L. M., Kalkbrenner, K. J., Bromberg, J. I., Basili, L. A., Calzone, K., Stopfer, J. E., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.10.2135 · Cited by 143
Early onset HER2‐positive breast cancer is associated with germline TP53 mutations
Melhem‐Bertrandt, A., Bojadzieva, J., Ready, K. J., Obeid, E. I., Liu, D. D., Gutierrez‐Barrera, A. M., Litton, J. K., Olopade, O. I., Hortobágyi, G. N., Strong, L. C., et al. (2011) · Cancer · doi:10.1002/cncr.26377 · Cited by 142
Targeting p53 for enhanced radio- and chemo-sensitivity
Lü, C., & El‐Deiry, W. S. (2009) · APOPTOSIS · doi:10.1007/s10495-009-0330-1 · Cited by 138
Palmero, E. I., Schüler‐Faccini, L., Caleffi, M. M., Achatz, M. I., Olivier, M., Martel‐Planche, G., Marcel, V., de Aguiar, E. S., Giacomazzi, J., Ewald, I. P., et al. (2008) · Cancer Letters · doi:10.1016/j.canlet.2007.10.044 · Cited by 132
Covalent and noncovalent modifiers of the p53 protein
Jayaraman, L., & Prives, C. L. (1999) · Cellular and Molecular Life Sciences · doi:10.1007/s000180050271 · Cited by 132
Variable Levels of Chromosomal Instability and Mitotic Spindle Checkpoint Defects in Breast Cancer
Yoon, D.-S., Wersto, R. P., Zhou, W., Chrest, F. J., Garrett, E. S., Kwon, T. K., & Gabrielson, E. W. (2002) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)64194-6 · Cited by 131
Recommendations on Predictive Testing for Germ Line p53 Mutations Among Cancer-Prone Individuals
Li, F. P., Garber, J. E., Friend, S. H., Strong, L. C., Patenaude, A. F., Juengst, E. T., Reilly, P. R., Correa, P., & Fraumeni, J. F. (1992) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/84.15.1156 · Cited by 126
A novel HER2-positive breast cancer phenotype arising from germline TP53 mutations: Table 1
Wilson, J. R. F., Bateman, A. C., Hanson, H., An, Q., Evans, G., Rahman, N., Jones, J. L., & Eccles, D. M. (2010) · Journal of Medical Genetics · doi:10.1136/jmg.2010.078113 · Cited by 122
Genetic Testing in Li-Fraumeni Syndrome: Uptake and Psychosocial Consequences
板東, 充., Aaronson, N. K., Wagner, A., Sijmons, R. H., Ausems, M. G. E. M., Vriends, A. H. J. T., Ruijs, M. W. G., van Os, T. A. M., Spruijt, L., Gómez-García, E. B., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.2112 · Cited by 118
Prevalence of Early Onset Colorectal Cancer in 397 Patients With Classic Li–Fraumeni Syndrome
Wong, P., Verselis, S. J., Garber, J. E., Schneider, K. A., DiGianni, L. M., Stockwell, D. H., Li, F. P., & Syngal, S. (2006) · Gastroenterology · doi:10.1053/j.gastro.2005.10.014 · Cited by 111
Ruijs, M., Schmidt, M. K., Nevanlinna, H. A., Tommiska, J., Aittomäki, K., Pruntel, R., Verhoef, S., & Veer, L. J. V. (2006) · European Journal of Human Genetics · doi:10.1038/sj.ejhg.5201715 · Cited by 108
Varley, J. M., Thorncroft, M. R., McGown, G., Appleby, J. E., Kelsey, A. M., Tricker, K. J., Evans, D. G., & Birch, J. M. (1997) · Oncogene · doi:10.1038/sj.onc.1201041 · Cited by 105
Masciari, S., den Abbeele, A. D. V., Diller, L., Rastarhuyeva, I., Yap, J., Schneider, K., Digianni, L., Li, F. P., Fraumeni, J. F., Syngal, S., et al. (2008) · JAMA · doi:10.1001/jama.299.11.1315 · Cited by 101
Frébourg, T., Kassel, J., Lam, K. T., Gryka, M. A., Barbier, N., Andersen, T. I., Børresen‐Dale, A., & Friend, S. H. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.14.6413 · Cited by 97
Krutilkova, V., Trková, M., Fleitz, J. M., Gregor, V., Novotna, K., Křepelová, A., Sumerauer, D., Kodet, R., Širůčková, S., Plevová, P., et al. (2005) · European Journal of Cancer · doi:10.1016/j.ejca.2005.01.026 · Cited by 97
Vogt Sionov, R., Coen, S., Goldberg, Z., Berger, M., Bercovich, B., Ben-Neriah, Y., Ciechanover, A., & Haupt, Y. (2001) · Molecular and Cellular Biology · doi:10.1128/mcb.21.17.5869-5878.2001 · Cited by 94
Mouchawar, J., Korch, C. T., Byers, T., Pitts, T. M., Li, E., McCredie, M. R. E., Giles, G. G., Hopper, J. L., & Southey, M. C. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-0851 · Cited by 92
Jenkins, J. R., Chumakov, P. M., Addison, C. M., Stürzbecher, H. W., & Wade-Evans, A. M. (1988) · Journal of Virology · doi:10.1128/jvi.62.10.3903-3906.1988 · Cited by 89
Routine TP53 testing for breast cancer under age 30: ready for prime time?
McCuaig, J. M., Armel, S. R., Novokmet, A., Ginsburg, O., Demsky, R., Narod, S. A., & Malkin, D. M. (2012) · Familial Cancer · doi:10.1007/s10689-012-9557-z · Cited by 89
Self-citationAndrogen-secreting adrenal tumors
Cordera, F., Grant, C. S., van Heerden, J., Thompson, G. B., & Young, W. F. (2003) · Surgery · doi:10.1016/s0039-6060(03)00410-0 · Cited by 85
Towards an understanding of the role of p53 in adrenocortical carcinogenesis
Wasserman, J. D., Zambetti, G. P., & Malkin, D. (2012) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2011.09.010 · Cited by 84
Self-citationInherited predisposition to breast and ovarian cancer.
Rowell, S., Newman, B. M., Boyd, J. A., & King, M. (1994) · PubMed · Cited by 83
Bougeard, G., Brugières, L., Chompret, A., Gesta, P., Charbonnier, F., Valent, A., Martin, C., Raux, G., Feunteun, J., Paillerets, B. B., et al. (2003) · Oncogene · doi:10.1038/sj.onc.1206155 · Cited by 82
Marcel, V., Palmero, E. I., Falagan-Lotsch, P., Martel‐Planche, G., Ashton‐Prolla, P., Olivier, M., Brentani, H., Hainaut, P. L., & Achatz, M. I. (2009) · Journal of Medical Genetics · doi:10.1136/jmg.2009.066704 · Cited by 81
The p53 gene in pediatric therapy-related leukemia and myelodysplasia
Felix, C., Hosler, M. R., Provisor, D., Salhany, K., Sexsmith, E., Slater, D., Cheung, N., Winick, N., Strauss, E., Heyn, R. M., et al. (1996) · Blood · doi:10.1182/blood.v87.10.4376.bloodjournal87104376 · Cited by 80
Self-citationSodha, N., Williams, R., Mangion, J., Bullock, S. L., Yuille, M., & Eeles, R. A. (2000) · Science · doi:10.1126/science.289.5478.359a · Cited by 80
Achatz, M. I., Hainaut, P. L., & Ashton‐Prolla, P. (2009) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70089-0 · Cited by 79
Preimplantation Genetic Diagnosis for Cancer Syndromes
Offit, K., Sagi, M., & Hurley, K. E. (2006) · JAMA · doi:10.1001/jama.296.22.2727 · Cited by 76
Bougeard, G., Limacher, J. M., Martin, C., CHARBONNIER, F., Killian, A., Delattre, O., Longy, M., Jonveaux, P., FRICKER, J.-P., Stoppa‐Lyonnet, D., et al. (2001) · Journal of Medical Genetics · doi:10.1136/jmg.38.4.253 · Cited by 76
In vitro analysis of the dominant negative effect of p53 mutants
Chêne, P. (1998) · Journal of Molecular Biology · doi:10.1006/jmbi.1998.1897 · Cited by 72
Psychosocial aspects of genetic testing
Cameron, L. D., & Muller, C. (2009) · Current Opinion in Psychiatry · doi:10.1097/yco.0b013e3283252d80 · Cited by 72
Regular surveillance for Li-fraumeni syndrome: advice, adherence and perceived benefits
Lammens, C. R. M., Bleiker, E. M. A., Aaronson, N. K., Wagner, A., Sijmons, R. H., Ausems, M. G. E. M., Vriends, A. H. J. T., Ruijs, M., van Os, T. A. M., Spruijt, L., et al. (2010) · Familial Cancer · doi:10.1007/s10689-010-9368-z · Cited by 70
Genetic Mapping of a Third Li-Fraumeni Syndrome Predisposition Locus to Human Chromosome 1q23
Bachinski, L. L., Olufemi, S.-E., Zhou, X., Wu, C., Yip, L., Shete, S. S., Lozano, G., Amos, C. I., Strong, L. C., & Krahe, R. (2005) · Cancer Research · doi:10.1158/0008-5472.427.65.2 · Cited by 69
A functional screen for germ line p53 mutations based on transcriptional activation.
Frébourg, T., Barbier, N., Kassel, J., Ng, Y. S., Beer‐Romero, P., & Friend, S. H. (1992) · PubMed · Cited by 67
Characterization of germline TP53 splicing mutations and their genetic and functional analysis
Varley, J. M., Attwooll, C. L., White, G. R. M., McGown, G., Thorncroft, M. R., Kelsey, A. M., Greaves, M. J., Boyle, J. M., & Birch, J. M. (2001) · Oncogene · doi:10.1038/sj.onc.1204369 · Cited by 62
Bihan-Benjamin, C. L., Moutou, C., Brugières, L., Feunteun, J., & Bonaïti‐Pellié, C. (1995) · Genetic Epidemiology · doi:10.1002/gepi.1370120103 · Cited by 61
Goi, K., Takagi, M., Iwata, S., Delia, D., Asada, M., Donghi, R., Tsunematsu, Y., Nakazawa, S., Yamamoto, H., Yokota, J., et al. (1997) · PubMed · Cited by 61
Increasing evidence that germline mutations inCHEK2do not cause Li-Fraumeni syndrome
Sodha, N., Houlston, R. S., Bullock, S. L., Yuille, M., Chu, C., Turner, G., & Eeles, R. A. (2002) · Human Mutation · doi:10.1002/humu.10136 · Cited by 60
Trková, M., Procházková, K., Krutilkova, V., Sumerauer, D., & Sedláček, Z. (2007) · Cancer · doi:10.1002/cncr.22834 · Cited by 60
Constitutional CHEK2 mutations are associated with a decreased risk of lung and laryngeal cancers
Cybulski, C., Masojc, B., Oszutowska–Mazurek, D., Jaworowska, E., Grodzki, T., Waloszczyk, P., Serwatowski, P., Pankowski, J., Huzarski, T., Byrski, T., et al. (2008) · Carcinogenesis · doi:10.1093/carcin/bgn044 · Cited by 58
Radiotherapy in the Treatment of Hereditary Breast Cancer
Pierce, L. J., & Haffty, B. G. (2010) · Seminars in Radiation Oncology · doi:10.1016/j.semradonc.2010.08.008 · Cited by 50
Delia, D., Goi, K., Mizutani, S., et al. (1997) · Oncogene · doi:10.1038/sj.onc.1201050 · Cited by 49
Chromosome instability is a predominant trait of fibroblasts from Li-Fraumeni families
Boyle, J. M., Mitchell, E. L. D., Greaves, M. J., Roberts, S., Tricker, K. J., Burt, E., Varley, J. M., Birch, J. M., & Scott, D. (1998) · British Journal of Cancer · doi:10.1038/bjc.1998.364 · Cited by 49
The contribution of CHEK2 to the TP53-negative Li-Fraumeni phenotype
Ruijs, M., Broeks, A., Menko, F. H., Ausems, M. G. E. M., Wagner, A., Oldenburg, R. A., Meijers-Heijboer, H. E. J., Veer, L. J. V., & Verhoef, S. (2009) · Hereditary Cancer in Clinical Practice · doi:10.1186/1897-4287-7-4 · Cited by 46
Peterson, S. K., Pentz, R. D., Marani, S. K., Ward, P. A., Blanco, A. M., LaRue, D. M., Vogel, K. J., Solomon, T., & Strong, L. C. (2008) · Psycho-Oncology · doi:10.1002/pon.1352 · Cited by 45
p53 compound heterozygosity in a severely affected child with Li-Fraumeni Syndrome
Quesnel, S., Verselis, S. J., Portwine, C., Garber, J. E., White, M. B., Feunteun, J., Malkin, D. M., & Li, F. P. (1999) · Oncogene · doi:10.1038/sj.onc.1202783 · Cited by 45
Self-citationSrivastava, S. K., Wang, S., Tong, Y. A., Pirollo, K. F., & Chang, E. H. (1993) · PubMed · Cited by 45
Wagner, A., Tops, C., Wijnen, J. T., Zwinderman, A. H., van der Meer, C., Kets, M., Niermeijer, M. F., Klijn, J. G. M., Tibben, A., Vasen, H. F. A., et al. (2002) · Journal of Medical Genetics · doi:10.1136/jmg.39.11.833 · Cited by 44
A Common Molecular Mechanism Underlies Two Phenotypically Distinct 17p13.1 Microdeletion Syndromes
Shlien, A., Baskin, B., Achatz, M. I., Stavropoulos, D. J., Nichols, K. E., Hudgins, L., Morel, C. F., Adam, M. P., Zhukova, N., Rotin, L. E., et al. (2010) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2010.10.007 · Cited by 43
Self-citationFang, S., Krahe, R., Lozano, G., Han, Y., Chen, W., Post, S. M., Zhang, B., Wilson, C. D., Bachinski, L. L., Strong, L. C., et al. (2010) · PLoS ONE · doi:10.1371/journal.pone.0010813 · Cited by 43
Is there anticipation in the age at onset of cancer in families with Li-Fraumeni syndrome?
Trková, M., Hladíková, M., Kasal, P., Goetz, P., & Sedláček, Z. (2002) · Journal of Human Genetics · doi:10.1007/s100380200055 · Cited by 42
Lammens, C. R. M., Bleiker, E. M. A., Verhoef, S., Ausems, M. G. E. M., Majoor‐Krakauer, D. F., Sijmons, R. H., Hes, F. J., Gómez-García, E. B., van Os, T. A. M., Spruijt, L., et al. (2011) · Psycho-Oncology · doi:10.1002/pon.1951 · Cited by 40
Camplejohn, R., Perry, P., Hodgson, S. V., Turner, G. S., Williams, A. C., Upton, C., MacGeoch, C., Mohammed, S. N., & Barnes, D. M. (1995) · British Journal of Cancer · doi:10.1038/bjc.1995.390 · Cited by 37
The TP53 mutational spectrum and frequency of CHEK2*1100delC in Li–Fraumeni-like kindreds
Siddiqui, R., Onel, K., Facio, F. M., Nafa, K., Díaz, L. R., Kauff, N. D., Huang, H. J., Robson, M. E., Ellis, N. A., & Offit, K. (2005) · Familial Cancer · doi:10.1007/s10689-004-1946-5 · Cited by 33
Wu, C., Krahe, R., Lozano, G., Zhang, B., Wilson, C. D., Jo, E.-J., Amos, C. I., Shete, S. S., & Strong, L. C. (2011) · Human Genetics · doi:10.1007/s00439-011-0957-1 · Cited by 32
Celebrating preimplantation genetic diagnosis of p53 mutations in Li-Fraumeni syndrome
Simpson, J. L. (2001) · Reproductive BioMedicine Online · doi:10.1016/s1472-6483(10)61953-0 · Cited by 31
Childhood predictive genetic testing for Li–Fraumeni syndrome
Evans, D. G., Lunt, P. W., Clancy, T., & Eeles, R. A. (2009) · Familial Cancer · doi:10.1007/s10689-009-9245-9 · Cited by 29
Exclusion of the genes CDKN2 and PTEN as causative gene defects in Li–Fraumeni syndrome
Burt, E. C., McGown, G., Thorncroft, M. R., James, L. M., Birch, J. M., & Varley, J. M. (1999) · British Journal of Cancer · doi:10.1038/sj.bjc.6690313 · Cited by 27
Generation or birth cohort effect on cancer risk in Li–Fraumeni syndrome
Brown, B. W., Costello, T. J., Hwang, S., & Strong, L. C. (2005) · Human Genetics · doi:10.1007/s00439-005-0016-x · Cited by 23
Ganjavi, H., & Malkin, D. M. (2002) · Clinical Orthopaedics and Related Research · doi:10.1097/00003086-200208000-00011 · Cited by 18
Self-citationAbsence of germline p16 INK4a alterations in p53 wild type Li-Fraumeni syndrome families
Portwine, C., LEES, J., VERSELIS, S., et al. (2000) · Journal of Medical Genetics · doi:10.1136/jmg.37.8.e13 · Cited by 18
Fang, S., Krahe, R., Bachinski, L. L., Zhang, B., Amos, C. I., & Strong, L. C. (2011) · Human Genetics · doi:10.1007/s00439-011-1039-0 · Cited by 14
Potential of Advexin ® : A p53 Gene-Replacement Therapy in Li–Fraumeni Syndrome
Nemunaitis, J., & Nemunaitis, J. J. (2008) · Future Oncology · doi:10.2217/14796694.4.6.759 · Cited by 14
Finková, A., Vazna, A., Hrachovina, O., Bendová, Š., Procházková, K., & Sedláček, Z. (2009) · Cancer Genetics and Cytogenetics · doi:10.1016/j.cancergencyto.2009.04.014 · Cited by 7
(1990) · PubMed
Cited by
Daly, M. B., Pal, T., Berry, M. P., Buys, S. S., Dickson, P., Domchek, S. M., Elkhanany, A., Friedman, S., Goggins, M., Hutton, M. L., et al. (2021) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2021.0001 · Cited by 1,112
Revisiting Li-Fraumeni Syndrome From TP53 Mutation Carriers
Bougeard, G., Renaux-Petel, M., Flaman, J.-M., Charbonnier, C., Fermey, P., Belotti, M., Gauthier-Villars, M., Stoppa-Lyonnet, D., Consolino, E., Brugières, L., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.59.5728 · Cited by 760
Tumor suppressor p53: Biology, signaling pathways, and therapeutic targeting
Hernández Borrero, L. J., & El-Deiry, W. S. (2021) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2021.188556 · Cited by 748
The genomic landscape of hypodiploid acute lymphoblastic leukemia
Holmfeldt, L., Wei, L., Diaz-Flores, E., Walsh, M., Zhang, J., Ding, L., Payne-Turner, D., Churchman, M., Andersson, A., Chen, S.-C., et al. (2013) · Nature Genetics · doi:10.1038/ng.2532 · Cited by 731
Cancer Screening Recommendations for Individuals with Li-Fraumeni Syndrome
Kratz, C. P., Achatz, M. I., Brugières, L., Frebourg, T., Garber, J. E., Greer, M.-L. C., Hansford, J. R., Janeway, K. A., Kohlmann, W. K., McGee, R., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-0408 · Cited by 534
Self-citation
Metadata
- Authors
- Malkin, D.
- Venue
- Genes & Cancer
- Publisher
- SAGE Publications
- Published
- 2011-04-01
- Volume
- 2
- Issue
- 4
- Pages
- 475-484
- ISSN
- 1947-6019 (ISSN-L)
- 1947-6027
- OpenAlex
- W2095909899
- Cited by
- 508
- References
- 169
- FWCI
- 11.99
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.